Pancreatic cancer orthotopic graft in a murine model
Authors:
- Milena MuzzoliniMMMilena Muzzolini
- Ismahane BelhabibIBIsmahane Belhabib
- Victoire CardotVCVictoire Cardot
- Annemilaï Tijeras-RaballandATAnnemilaï Tijeras-Raballand
- Cindy NeuzilletCNCindy Neuzillet
- Corinne BousquetCBCorinne Bousquet
- Renato Micelli LupinacciRLRenato Micelli Lupinacci
- Christine JeanCJChristine Jean
Open Access
- 1 January 2023
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Acta Cirurgica Brasileira
- Vol. 38, e382823
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with increasing incidence. Even if progress have been made, the five-year overall survival remains lower than 10%. There is a desperate need in therapeutic improvements. In the last two decades, new in-vitro models have been developed and improved, including tridimensional-culture spheroids and organoids. However, animal studies remain mandatory in the upscaling before clinical studies. Orthotopic and syngeneic grafting is a robust model to test a drug efficiency in a tumor and its microenvironment.Keywords
This publication has 22 references indexed in Scilit:
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2015
- Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer modelBMC Cancer, 2015
- Organoid Models of Human and Mouse Ductal Pancreatic CancerCell, 2015
- Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United StatesCancer Research, 2014
- Influence of Interferon-Alpha Combined with Chemo (Radio) Therapy on Immunological Parameters in Pancreatic AdenocarcinomaInternational Journal of Molecular Sciences, 2014
- Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluationWorld Journal of Gastroenterology, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Mouse models of pancreatic cancerWorld Journal of Gastroenterology, 2012
- Pancreatic cancerThe Lancet, 2011
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011